Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · IEX Real-Time Price · USD
45.12
-4.11 (-8.35%)
At close: May 3, 2024, 4:00 PM
46.00
+0.88 (1.95%)
After-hours: May 3, 2024, 6:37 PM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 33 employees on December 31, 2023. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
n/a
Profits / Employee
-$1,181,455
Market Cap
1.51B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 33 | 1 | 3.13% |
Dec 31, 2022 | 32 | 1 | 3.23% |
Dec 31, 2021 | 31 | 0 | - |
Dec 31, 2020 | 31 | 6 | 24.00% |
Dec 31, 2019 | 25 | 2 | 8.70% |
Dec 31, 2018 | 23 | 5 | 27.78% |
Dec 31, 2017 | 18 | -11 | -37.93% |
Dec 31, 2016 | 29 | -13 | -30.95% |
Dec 31, 2015 | 42 | 23 | 121.05% |
Dec 31, 2014 | 19 | 6 | 46.15% |
Dec 31, 2013 | 13 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Myriad Genetics | 2,700 |
Zai Lab | 2,175 |
Taro Pharmaceutical Industries | 1,554 |
Schrödinger | 867 |
Supernus Pharmaceuticals | 652 |
Ardelyx | 267 |
Inhibrx | 172 |
SLNO News
- 1 day ago - Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock - GlobeNewsWire
- 2 days ago - Soleno Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 days ago - Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome - GlobeNewsWire
- 5 days ago - Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) - GlobeNewsWire
- 15 days ago - Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Soleno Therapeutics to Present at Upcoming February Investor Conferences - GlobeNewsWire